Together, these data provide a cellular, and molecular explanation for enhanced cytokine signaling in LMO2-driven ETP-ALL beyond activating mutations, and a rationale for inclusion of type I FLT3 inhibitors as a new precision medicine approach for FLT3-expressing ETP-ALL. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.